Seborrheic dermatitis and atopic dermatitis are well recognized
as common facial dermatoses. Both irritant and allergic contact dermatitis may involve any anatomic location,
with facial involvement sometimes noted depending on the contactants involved and patterns of cutaneous exposure.
Facial psoriasis is perceived to be relatively uncommon by comparison, however, facial skin may be affected in 17% to 46% of patients with psoriasis.1 Atopic dermatitis flares may sometimes be localized to the eyelids and/or the post auricular region, with or without involvement of other facial areas.2
The most commonly encountered skin disorders that fall under
the umbrella of corticosteroid-responsive dermatoses are seborrheic dermatitis, psoriasis (plaque type), and eczematous dermatoses such as atopic dermatitis and contact dermatitis, As these entities are very common, therapies for these disorders
are well established and widely published. However, data are more limited on the treatment of only facial involvement for most of these disorders. Even with larger clinical trials, subset
analyses evaluating efficacy and safety with treatment of the face alone is not typically reported. Therapeutic response and adverse event profiles related to specific treatments of facial
skin involve unique challenges, as the patient's desire for a more rapid response is usually greater, and visible adverse reactions
are more psychologically bothersome to many patients, especially those that may be persistent.
Facial skin is different from other body locations in a number of ways.3 The skin on the face is thinner and pilosebaceous units are much more numerous. Due to regular exposure of facial skin to environmental factors, climatic changes, and many contactants,
such as products used for personal hygiene, skin care,
↑ back to top